 Your new post is loading...
 Your new post is loading...
|
Scooped by
Gilbert C FAURE
November 14, 2:13 AM
|
The blood-brain barrier (BBB) is typically defined by what it keeps out. New work from Gladstone Institutes scientist and Arc Innovation Investigator Andrew Yang and team maps what it imports, finding a “transportome” of 92 plasma proteins that the BBB routes to particular brain cell types.
The team labeled donor mice plasma with trans-cyclooctene, injected it into mice, and used click chemistry to pull the labeled plasma out of brain tissue. Of 861 plasma proteins, 670 never reached the brain, 99 stopped in vessels, and 92 crossed into the parenchyma, most of them made in the liver, adipose tissue, and intestine. BBB crossing tracked with alpha-helical content rather than protein size, consistent with receptor-mediated transport rather than leakage.
Individual proteins then went to particular cell types, with APOA1 accumulating in astrocytes and SERPINA1 in microglia. APOA1 crosses through endothelial SR-B1 and engages astrocytic ABCA1, a key Alzheimer’s risk gene. In culture, APOA1 drove astrocytes to release cholesterol, and their conditioned medium raised PSD-95 and dendritic spine density in neurons. The receiving cell sets the destination, and raising SR-B1 on neurons pulled APOA1 into neurons instead.
In early-stage 5xFAD mice, an amyloid model of Alzheimer’s, transport was remodeled while the BBB was still intact. Uptake fell for three proteins, including APOA1, and rose for four, including SERPINA1. SR-B1 was reduced on endothelial cells, and ABCA1 was reduced on astrocytes, which were accumulating lipids. Under LPS, a damaged barrier let 225 plasma proteins leak in at once. The 5xFAD changes are the converse.
Driving APOA1 production in the liver for 2.5 months raised its levels in 5xFAD brains. Astrocyte lipid and GFAP fell, synaptic density rose, plaque shrank in the dentate gyrus, and mice partially recovered performance in a spatial memory test, all with nothing being administered to the brain.
The brain depends on proteins it doesn’t make to cross the BBB from the periphery. Losing them is a “systemic withdrawal” distinct from leakage, and one that could be addressed by changing what the body supplies.
All 92 permeable proteins are in a searchable browser: https://lnkd.in/gHyK5Xxe
- See the paper in Cell by Cell Press: https://lnkd.in/gHjMYXAy - Learn more: https://lnkd.in/gPzi6Wsv | 11 comments on LinkedIn
|
Scooped by
Gilbert C FAURE
October 24, 4:23 AM
|
Does sleep deprivation affect the brain's ability to clear waste, and what might that mean for Alzheimer’s disease?
In our latest preprint, we combine glymphatic MRI with Bayesian inference and mathematical modelling to estimate CSF tracer clearance rates across the living human brain.
🧠 Regional brain clearance is strongly organised and broadly consistent across individuals. It is among the fastest in the entorhinal cortex, where tau pathology typically first appears, and declines across the Braak hierarchy.
😴 Just one night of sleep deprivation was associated with approximately one-third lower clearance across the brain, while the regional pattern remained largely unchanged.
📈 The overall clearance level and its spatial pattern play distinct roles in simulated tau propagation. Using these estimated clearance maps in a mathematical model of tau spreading across the connectome, we found that the overall clearance level sets the pace of simulated pathology, while the spatial pattern of clearance modifies local vulnerability and the course of progression.
Spatially organised clearance may be a missing piece of the neurodegeneration puzzle. Our findings suggest that both how fast the brain clears waste and the spatial pattern of clearance may be important for understanding the progression of proteinopathies.
A truly interdisciplinary collaboration across Oxford Mathematics, Simula Research Laboratory, Oslo University Hospital and beyond. Thank you to my brilliant co-authors Travis Thompson, Hadrien Oliveri, Vegard Vinje, Geir Ringstad, Per Kristian Eide, Alain Goriely and Marie E. Rognes.
📄 https://lnkd.in/ezSCbhgz #Neuroscience #SleepResearch #Glymphatic #AlzheimersDisease #MathematicalModelling
|
Scooped by
Gilbert C FAURE
October 16, 10:45 AM
|
Complement comprises a group of plasma and membrane proteins that provide an effective bridging function for innate and adaptive humoral immunity. Understanding complement pathophysiology is fundamental given that inappropriate complement function in host defence can lead to infectious diseases and inefficient disposal of altered, damaged or senescent cells can lead to or enhance autoimmune neurological processes. Although the rising number of approved drugs targeting complement pathways remains primarily focused on diseases with complement-fixing pathogenic antibodies (such as myasthenia gravis and neuromyelitis optica spectrum disorder), a robust pipeline of emerging treatments holds promise for expanding complement-targeted therapies to a broader spectrum of autoimmune neurological diseases, such as multiple sclerosis and even neurodegenerative diseases such as Alzheimer disease or amyotrophic lateral sclerosis. This Review presents insights into complement biology as it relates to the development or initiation of autoimmune and possibly degenerative diseases affecting the central and peripheral nervous systems or muscle. The effects, merits, risks and challenges of marketed drugs or biologic agents in ongoing phase I–III clinical trials engineered to inhibit proximal or distal components of the complement cascade are also discussed. Anti-complement therapeutics are destined to change the treatment of autoimmune neurologic conditions in which the therapeutic landscape is now becoming crowded with biologic agents targeting other key autoimmunity factors. This Review outlines the main components of the complement cascade associated with initiating or propagating the progression of key autoimmune neurological diseases. The authors also highlight how current and emerging complement-targeted therapeutics are destined to redefine treatment paradigms.
|
Scooped by
Gilbert C FAURE
August 1, 2:12 AM
|
New research from Trinity College Dublin is changing how scientists think about Alzheimer’s disease.
Researchers have discovered that microglia, the brain’s immune cells, do more than drive inflammation. They also help keep the brain’s electrical activity stable. When these cells were reduced in an Alzheimer’s model, brain activity became more abnormal and seizure-like episodes increased, suggesting that some experimental treatments could have unintended consequences.
The study, led by Dr Hugh Delaney with senior authors Prof Mark Cunningham (School of Medicine, Trinity College Dublin) and Prof colm cunningham (Trinity School Biochemistry and Immunology), highlights the complexity of Alzheimer’s disease and the importance of understanding the brain’s own protective mechanisms.
The findings suggest that future therapies should target harmful inflammation while preserving the beneficial roles these cells play in maintaining healthy brain function.
Published in the journal Brain, this research is an important step towards developing safer and more effective treatments for the more than 55 million people worldwide living with Alzheimer’s disease.
Congratulations to Hugh, Mark, Colm and all the Trinity researchers involved in this important work. To read the full article, click here: https://lnkd.in/dTAMwtnq
|
Scooped by
Gilbert C FAURE
January 14, 1:06 PM
|
Targeting TREM2 has emerged as an attractive therapeutic strategy for Alzheimer’s disease, with multiple monoclonal antibodies and small-molecule agonists advancing into clinical development in recent years.
TREM2 is a microglial transmembrane receptor that plays key roles in innate immune signaling, microglial survival, and responses to amyloid-β and tau pathology. While early antibody programs have yet to demonstrate clear clinical benefit, they have generated valuable insights into target biology, pharmacology, and clinical trial design.
This target review covers the evolving TREM2 landscape, including lessons from first-generation antibodies, emerging small-molecule agonists, and how recent clinical and patent activity is renewing momentum around this target.
Explore our target review on emerging TREM2 agonists.
|
Scooped by
Gilbert C FAURE
December 11, 2025 1:47 PM
|
|
Scooped by
Gilbert C FAURE
February 13, 2025 6:48 AM
|
There is a misconception that only amyloid-targeting treatments have been studied in Alzheimer's disease. The reality is that clinical trials have evaluated… | 21 comments on LinkedIn
|
Scooped by
Gilbert C FAURE
January 12, 2025 5:34 AM
|
Long COVID (also known as post-acute sequelae of SARS-CoV-2 infection [PASC] or post-COVID syndrome) is characterized by persistent symptoms that extend beyond the acute phase of SARS-CoV-2 infection, affecting approximately 10% to over 30% of those infected. It presents a significant clinical challenge, notably due to pronounced neurocognitive symptoms such as brain fog. The mechanisms underlying these effects are multifactorial, with mounting evidence pointing to a central role of cerebromicrovascular dysfunction. This review investigates key pathophysiological mechanisms contributing to cerebrovascular dysfunction in long COVID and their impacts on brain health. We discuss how endothelial tropism of SARS-CoV-2 and direct vascular infection trigger endothelial dysfunction, impaired neurovascular coupling, and blood–brain barrier disruption, resulting in compromised cerebral perfusion. Furthermore, the infection appears to induce mitochondrial dysfunction, enhancing oxidative stress and inflammation within cerebral endothelial cells. Autoantibody formation following infection also potentially exacerbates neurovascular injury, contributing to chronic vascular inflammation and ongoing blood–brain barrier compromise. These factors collectively contribute to the emergence of white matter hyperintensities, promote amyloid pathology, and may accelerate neurodegenerative processes, including Alzheimer’s disease. This review also emphasizes the critical role of advanced imaging techniques in assessing cerebromicrovascular health and the need for targeted interventions to address these cerebrovascular complications. A deeper understanding of the cerebrovascular mechanisms of long COVID is essential to advance targeted treatments and mitigate its long-term neurocognitive consequences.
|
Scooped by
Gilbert C FAURE
December 19, 2024 7:01 AM
|
The evolving pathophysiological landscape of Alzheimer’s disease (AD) research increasingly indicates an intricate interplay between the brain and the immune… | 18 comments on LinkedIn
In 2006, Sylvain Lesné and seven coauthors published a paper on Alzheimer’s disease, “A specific amyloid-beta protein assembly in the brain impairs memory,” in Nature, the world’s most prestigious scientific journal.
|
Scooped by
Gilbert C FAURE
February 23, 2024 10:38 AM
|
/PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of...
|
Scooped by
Gilbert C FAURE
December 17, 2023 11:52 AM
|
Park J, Simpson C, Patel K. Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease. Ann Pharmacother. 2023 Dec 14;:10600280231218253. PubMed.
|
Scooped by
Gilbert C FAURE
October 25, 2023 10:37 AM
|
healthcare,medical,study,heart,medicine,medcalc,qtc,calculator,Insurance,Cord Blood ,mesothelioma,survival rates,structured settlement annuity companies,small business administration sba,Heart,Cardiology,Health,Fitness,Medical ,ikaria wariootia,iran aryaee tv,epidemiologist pronounce,how to...
|
|
Scooped by
Gilbert C FAURE
November 12, 7:20 AM
|
Alzheimer's &Dementia, Volume 22, Issue 11, November 2026.
|
Scooped by
Gilbert C FAURE
October 19, 4:26 AM
|
● Neurodegenerative diseases pose major clinical challenges partly due to the underappreciation of the brain’s vascular and clearance systems. Neurovascular dysfunction and glymphatic impairment are early contributors to disease onset, preceding established markers such as protein aggregation.
● The convergence of ■ BBB dysfunction, ■ Glymphatic impairment, and ■ Neuroinflammation, creates a self-perpetuating cycle that accelerates neurodegeneration through mechanisms that remain largely untargeted by current therapeutic approaches. This neurovascular dysfunction represents one of the earliest detectable changes in neurodegeneration, often preceding classical pathological markers by years or decades.
● Impaired glymphatic clearance is an important cause of metabolite accumulation in Alzheimer’s disease, as the disease is characterized by the abnormal accumulation of amyloid-β protein creating neuritic plaques and hyperphosphorylated tau protein forming neurofibrillary tangles. Multisensory gamma stimulation has been shown to promote glymphatic clearance, as glymphatic transport clears parenchymal metabolites, including pathogenic proteins such as amyloid-β. The glymphatic system, critically dependent on astrocytic AQP4 water channels for CSF-interstitial fluid exchange, becomes compromised when neurovascular integrity fails.
● Blood-brain barrier BBB breakdown, pericyte dysfunction, and compromised cerebral perfusion precede protein aggregation in multiple neurodegenerative disorders. Glymphatic dysfunction, characterized by aquaporin-4 (AQP4) depolarization and abnormalities in meningeal lymphatic vessels, impairs the clearance of neurotoxic metabolites.
● Novel therapeutic opportunities include the preservation of pericyte function, restoration of AQP4 polarity, enhancement of meningeal lymphatic drainage via vascular endothelial growth factor-C (VEGF-C)/vascular endothelial growth factor receptor-3 VEGFR-3 signaling, and targeted modulation of microRNA and complement pathways that regulate neuroinflammation. By targeting the earliest vascular and glymphatic disruptions, emerging therapeutic strategies may halt or delay disease progression before irreversible neuronal loss occurs. This neurovascular-glymphatic approach represents an unexplored frontier that complements traditional protein-centric therapeutic paradigms, offering new possibilities for early intervention in neurodegenerative disorders.
● The presented review identifies these three critical knowledge gaps that represent unprecedented therapeutic opportunities. These interconnected pathways offer novel pharmacological targets that could halt or reverse the neurodegenerative process before irreversible neuronal damage occurs. https://lnkd.in/dT3fjHjh This study highlights cross-sectional and longitudinal analyses of the GS in COVID-19 patients. https://lnkd.in/d6X95FKg #covid #glymphatic #neuroinflammation #BBB
|
Scooped by
Gilbert C FAURE
August 16, 3:51 AM
|
🧠 Alzheimer’s disease: should we also consider it a disease of innate immunity?
For decades, Alzheimer’s disease has been viewed primarily through the accumulation of amyloid-β (Aβ) and pathological tau protein. A more recent perspective is broadening this paradigm: innate immunity may be a central driver of the disease rather than merely a consequence of neurodegeneration.
The AD² hypothesis (Alzheimer’s disease as an autoimmune disease) proposes that Aβ may initially participate in a protective immune response. Infections, trauma, metabolic stress and other cellular injuries generate PAMPs and DAMPs, activating the brain’s innate immune machinery.
When this response persists, microglia, initially protective, may shift toward a dysfunctional phenotype. This can lead to chronic production of pro-inflammatory cytokines, inflammasome activation and recruitment of the complement system, particularly C1q and C3.
Complement may subsequently contribute to abnormal synaptic tagging and microglia-mediated synaptic elimination, progressively promoting synaptic dysfunction, neuronal loss and neurodegeneration.
Neuronal injury then releases additional DAMPs, further stimulating innate immunity and creating a self-perpetuating vicious cycle in which an initially protective immune response becomes chronic, dysregulated and potentially damaging to self.
This is the essence of the emerging concept of “innate autoimmunity”: Alzheimer’s disease may not simply be a proteinopathy, but a disorder in which innate immunity, microglia, inflammasomes and complement actively participate in neurodegenerative progression.
⚠️ Importantly, this remains an emerging pathophysiological hypothesis rather than a universally accepted classification of Alzheimer’s disease as an autoimmune disorder.
Rethinking Alzheimer’s disease through the lens of innate immunity may ultimately open new avenues for diagnosis, prevention and immune-targeted therapies.
|
Scooped by
Gilbert C FAURE
July 30, 3:42 AM
|
Can your voice help detect disease? 🎙️🤖🩺
Excited to share a major milestone in the field of AI-powered vocal biomarkers!
Researchers and clinicians from the Department of Precision Health (DoPH) at the Luxembourg Institute of Health and the University of South Florida (USF) have led an international effort to establish the first consensus-based framework and definitions for vocal biomarkers: a crucial step toward making voice-based disease detection more reliable, reproducible, and ready for clinical practice.
Led by Dr. Guy Fagherazzi (Head of the Department of Precision Health at LIH and Chair of eVoiceNet - COST Action Network) and Dr. Yael Bensoussan (USF Health Morsani College of Medicine and co-lead of Bridge2AI-Voice), this initiative brought together 24 experts from Europe and North America to create a shared scientific language for the field.
Why does this matter? 👇
🗣️ Our voices contain valuable information about our health 📊 AI can detect subtle changes linked to conditions such as Parkinson's disease, Alzheimer's disease, depression, heart failure, and type 2 diabetes 🤝 A common framework will accelerate collaboration, improve validation, and help bring trustworthy voice-based technologies from research labs to clinical care
🔗 Read the full article here and discover how AI and voice are shaping the future of precision health: https://lnkd.in/edHx32SK
#AI #VoiceAI #VocalBiomarkers #DigitalHealth #PrecisionHealth #HealthcareInnovation #ClinicalResearch #MachineLearning #LIH #eVoiceNet #Bridge2AI #HealthTech
|
Scooped by
Gilbert C FAURE
January 2, 5:08 AM
|
Emerging evidence highlights the crucial role of peripheral immune cells in maintaining brain homeostasis and their influence on the pathology of Alzheimer disease (AD). Genome-wide association studies have identified numerous AD risk variants in genes expressed by immune cells, implicating innate and adaptive immune pathways in disease progression. Advances in neuroimmunology have revealed that immune cell crosstalk involving T cells, B cells, monocytes and/or macrophages and neutrophils can modulate the hallmark features of AD, including amyloid plaque accumulation, tau pathology and chronic neuroinflammation. Mechanistic insights suggest that chronic peripheral inflammation, immune exhaustion, metabolic dysfunction and epigenetic reprogramming exacerbate neurodegeneration in AD by promoting toxic inflammation and impairing protein clearance in the brain. These findings may catalyse the development of novel immunomodulatory strategies, such as immune checkpoint inhibition and cytokine targeting, among others, for AD. This Review examines peripheral immune alterations in AD, evaluates related therapeutic opportunities and highlights key knowledge gaps, particularly the need for human-derived data to advance translational progress. Future research should prioritize personalized approaches that integrate genetic risk, immune profiling and ageing to inform next-generation therapies for AD. The importance of peripheral immunity in Alzheimer disease has gained much traction in recent years, mainly due to multiple genome-wide association studies identifying risk loci associated with genes expressed predominantly in the periphery. This review discusses the importance of peripheral immune cells in shaping brain physiology and their role in Alzheimer disease.
|
Scooped by
Gilbert C FAURE
July 17, 2025 8:07 AM
|
|
Scooped by
Gilbert C FAURE
January 13, 2025 4:45 AM
|
Kwon HS, Koh SH. Monoclonal Antibodies-A New Horizon in Alzheimer's Treatment. J Clin Neurol. 2025 Jan;21(1):1-2. PubMed.
|
Scooped by
Gilbert C FAURE
January 6, 2025 4:10 AM
|
I have started the new year reading many research articles on chronic inflammation. It is incredible to me how much chronic inflammation is a driver for almost…
|
Scooped by
Gilbert C FAURE
December 16, 2024 12:54 PM
|
Increasing evidence points to a pivotal role of immune processes in the pathogenesis of Alzheimer disease, which is the most prevalent neurodegenerative and dementia-causing disease of our time. Multiple lines of information provided by experimental, epidemiological, neuropathological and genetic studies suggest a pathological role for innate and adaptive immune activation in this disease. Here, we review the cell types and pathological mechanisms involved in disease development as well as the influence of genetics and lifestyle factors. Given the decade-long preclinical stage of Alzheimer disease, these mechanisms and their interactions are driving forces behind the spread and progression of the disease. The identification of treatment opportunities will require a precise understanding of the cells and mechanisms involved as well as a clear definition of their temporal and topographical nature. We will also discuss new therapeutic strategies for targeting neuroinflammation, which are now entering the clinic and showing promise for patients. This Review provides an in-depth examination of how inflammation contributes to neurodegeneration in Alzheimer disease. The authors explore the impact of extrinsic factors, such as brain trauma, diet and infections, and host-intrinsic factors, such as the activity of microglial cells and other immune, vascular and neuronal cell populations, on disease development. They also highlight emerging drugs that target this inflammatory component for therapy of Alzheimer disease.
|
Scooped by
Gilbert C FAURE
June 4, 2024 4:26 AM
|
The immunometabolism of microglia determines not only their own fate but also that of neurons and their function during aging and neurodegeneration.
|
Scooped by
Gilbert C FAURE
December 30, 2023 10:57 AM
|
Liu GP, Wang S. Editorial: New challenges and future perspectives in Alzheimer's disease and related dementias. Front Aging Neurosci. 2023;15:1345560. Epub 2023 Dec 12 PubMed.
|
Scooped by
Gilbert C FAURE
December 11, 2023 10:04 AM
|
Scientists believe a buildup of the brain protein amyloid beta plays a key role in the death of neurons, which can lead to Alzheimer's disease. Although most people develop some amyloid beta brain proteins as they age, researchers suspect abnormal forms of the protein of may be key to the...
|